| Project/Area Number |
23591016
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kanazawa Medical University |
|---|
Principal Investigator |
SHIMASAKI Takeo 金沢医科大学, 総合医学研究所, 講師 (50377420)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIGAKI Yasuhito 金沢医科大学, 総合医学研究所, 准教授 (20232275)
TOMOSUGI Naohisa 金沢医科大学, 総合医学研究所, 教授 (80155580)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MOTOO Yoshiharu 金沢医科大学, 医学部, 教授 (80210095)
MINAMOTO Toshinari 金沢大学, がん研究所, 教授 (50239323)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 化学療法 / EMT / ドラッグリポジショニング / 膵臓がん / GSK３β / 化学療法誘導性EMT / 膵臓癌治療薬 / GSK3β / 膵臓癌 |
|---|
| Research Abstract |
Pancreatic cancer is obstinate and results in a highly invasive and metastatic tumor phenotype that is a major obstacle to chemotherapy. We found that the pancreatic cancer cell lines exposed low concentration of gemcitabine triggered the cellular morphological change showing epithelial to mesenchymal transition (EMT) and up-regulated motility. These phenomenon are inhibited by GSK3beta inhibitor. We proposed a new strategy of inhibiting EMT-induced by chemotherapy by GSK3beta inhibiting drugs. In order to investigate the safety and antitumor response to this combination of GSK3beta inhibiting drugs, Investigator initiated phase I clinical trial are conducted with advanced pancreatic cancer. This research may contribute to the development of a new pancreatic cancer treatment.
|
